Mark Bustoros

Also affiliated with Cornell University, New York Hospital Queens, Presbyterian Hospital, Weill Cornell Medicine

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone”.

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Regular Aspirin Use and Mortality in Patients with Multiple Myeloma

Cancer Epidemiology Biomarkers & Prevention(2021)10.1158/1055-9965.epi-21-0946

N/A

0DataRank · unranked

2 citations

Dong Hoon Lee, Graham A. Colditz, Timothy R. Rebbeck, Bernard Rosner, Mark Bustoros +3 more

Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.10.471975

N/A

0DataRank · unranked

0 citations

Shankara Anand, Romanos Sklavenitis‐Pistofidis, Robert Redd, Eileen M. Boyle, Benny Zhitomirsky +22 more

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Cancer Cell(2022)10.1016/j.ccell.2022.10.017

N/A

0DataRank · unranked

64 citations

Michelle P. Aranha, Robert Redd, Joanna Bagińska, Nicholas J. Haradhvala, Margaret Hallisey +34 more

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Nature Communications(2022)10.1038/s41467-022-30694-w

N/A

0DataRank · unranked

33 citations

Shankara Anand, Romanos Sklavenitis‐Pistofidis, Robert Redd, Eileen M. Boyle, Benny Zhitomirsky +22 more

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

0DataRank · unranked

142 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Journal of Clinical Oncology(2020)10.1200/jco.20.00437

N/A

0DataRank · unranked

182 citations

Romanos Sklavenitis‐Pistofidis, Jihye Park, Robert Redd, Benny Zhitomirsky, Andrew Dunford +31 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more